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Impairment of insulin clearance is being increasingly recognized as a critical step in 
the development of insulin resistance and metabolic disease. The carcinoembryonic 
antigen-related cell adhesion molecule 1 (CEACAM1) promotes insulin clearance. Null 
deletion or liver-specific inactivation of Ceacam1 in mice causes a defect in insulin 
clearance, insulin resistance, steatohepatitis, and visceral obesity. Immunohistological 
analysis revealed reduction of hepatic CEACAM1 in obese subjects with fatty liver 
disease. Thus, we aimed to determine whether this occurs at the hepatocyte level 
in response to systemic extrahepatic factors and whether this holds across species. 
Northern and Western blot analyses demonstrate that CEACAM1 mRNA and protein 
levels are reduced in liver tissues of obese individuals compared to their lean age-
matched counterparts. Furthermore, Western analysis reveals a comparable reduction 
of CEACAM1 protein in primary hepatocytes derived from the same obese subjects. 
Similar to humans, Ceacam1 mRNA level, assessed by quantitative RT-PCR analysis, 
is significantly reduced in the livers of obese Zucker (fa/fa, ZDF) and Koletsky (f/f) rats 
relative to their age-matched lean counterparts. These studies demonstrate that the 
reduction of hepatic CEACAM1 in obesity occurs at the level of hepatocytes and identify 
the reduction of hepatic CEACAM1 as a common denominator of obesity across multiple 
species.
Keywords: insulin clearance, insulin resistance, obesity, carcinoembryonic antigen-related cell adhesion molecule 
1, hyperinsulinemia, fatty liver disease
inTrODUcTiOn
The carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is ubiquitously 
expressed (1). CEACAM1 protein is expressed highly in liver, but to an insignificant extent in white 
adipose tissue and skeletal muscle, among classical insulin target peripheral tissues (1). Upon its 
phosphorylation by the insulin receptor tyrosine kinase in the hepatocyte (2), CEACAM1 promotes 
the uptake of insulin via its receptor to be degraded and cleared (3, 4). Bolstering this function of 
CEACAM1, defective hepatic insulin clearance and subsequently, chronic hyperinsulinemia develops 
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in mice with global null mutation (Cc1−/−) or with liver-specific 
overexpression of the dominant-negative phosphorylation-
defective inactive isoform of Ceacam1 (L-SACC1) (5–7). At 
least in part by downregulating the insulin receptor number (8), 
chronic hyperinsulinemia causes insulin resistance in these mice 
(5–7). Consistent with its positive effect on de novo lipogenesis 
(9), hyperinsulinemia also causes hepatic lipid accumulation, as 
well as lipid redistribution to the white adipose depot for storage, 
resulting in elevated visceral obesity. Contributing to visceral 
obesity and increased total fat mass in Cc1−/− mice is leptin 
resistance, manifested by hyperphagia and reduced spontaneous 
physical activity (10).
In humans and rodents, high-fat diet causes insulin resistance 
and visceral obesity. Recent data from our laboratories show 
that high-fat intake causes a decrease in hepatic CEACAM1 
level by >50% within 3  weeks (11), and that this appears to 
play a causative role in diet-induced insulin resistance inso-
far as adenoviral-mediated delivery of CEACAM1 in liver 
reverses the metabolic abnormalities associated with increased 
fat intake, including insulin resistance, hepatosteatosis, and 
visceral obesity (12). Similarly, transgenic overexpression of 
CEACAM1 in liver protects against diet-induced insulin resist-
ance, visceral obesity, hepatosteatosis, and fibrosis in adipose 
tissue (11).
Together, this assigns a significant role for reduced hepatic 
CEACAM1 levels in hyperinsulinemia-driven metabolic abnor-
malities, including insulin resistance and hepatic steatosis in 
mice. It also provided the impetus to investigate whether reduc-
tion of hepatic CEACAM1 level occurs at the hepatocyte level and 
whether it is common in obesity across multiple species.
MaTerials anD MeThODs
animal care and husbandry
Obese male Zucker fatty (fa/fa—8  weeks of age) and Zucker 
Diabetic Fatty rats (ZDF—12  weeks of age), and Koletsky 
spontaneous hypertensive rats (f/f—16  weeks of age) and their 
age-matched lean controls were purchased from Charles River 
Laboratories. Rats were fed ad  libitum a regular chow diet and 
kept in a 12-h dark–light cycle. All procedures were approved 
by the Institutional Animal Care and Utilization Committee at 
the University of Toledo College of Medicine and Life Sciences 
(formerly known as the Medical College of Ohio). All experi-
ments were conducted in accordance with the recommendations 
of the committee, confirming to the Guide for the Care and Use 
of Laboratory Animals published by the US National Institutes of 
Health (NIH Publication No. 85-23, revised 1996).
assessment of Plasma Biochemistry
Biochemical parameters were assessed in plasma drawn from 
overnight fasted rats. Plasma insulin and C-peptide levels were 
determined by radioimmunoassays (Linco Research) and their 
molar ratio at steady state was calculated as a marker of insulin 
clearance. Plasma triglyceride (TG) levels were assayed by 
Triglycerides reagent (Pointe Scientific) and plasma free fatty 
acids (FFA) by NEFA C kit (Wako). Hepatic TG content was 
assayed in tissues separated by chloroform–methanol, as previ-
ously described (12).
human Primary hepatocytes
Livers and freshly isolated primary hepatocytes derived from the 
same lean and obese subjects were purchased from Cellzdirect 
(www.cellzdirect.com). The subjects include seven anonymous 
coded obese (body mass index >30  kg/m2) 45- to 50-year-old 
male subjects and four age-, sex-, and race-matched lean subjects. 
All subjects were non-smokers, non-alcoholics with no history 
of drug abuse, or other known health conditions or exposure to 
infectious diseases.
Specimens and cells were sent de-identified, labeled with a 
code with no other identifiable information. Hence, studies were 
exempted by the Institutional Review Board at the University of 
Toledo College of Medicine and Life Sciences (previously known 
as the Medical College of Ohio).
Western Blot analysis of human 
ceacaM1 Protein levels
Lysates from primary hepatocytes and liver were analyzed 
by 4–12% SDS-PAGE followed by immunoblotting (Ib) with 
polyclonal antibody against CEACAM1 (13), and normalization 
against GAPDH (Santa Cruz).
northern Blot analysis of rat Ceacam1 
mrna level
As previously described (11), Northern blot analysis was per-
formed on total liver RNA extracted by TRIzol (Invitrogen), 
purified by MicroPoly (A) Pure Kit (Ambion), and sequentially 
probed with cDNAs for Ceacam1 followed by Gapdh for 
normalization, using the Random Primed DNA Labeling Kit 
(Roche).
Quantitative rT-Pcr analysis of rat 
CEACAM1 mrna level
qRT-PCR was performed in homogenized liver lysates as 
routinely performed (14). Briefly, total RNA was extracted by 
TRIzol (GIBCO BRL) and first strand cDNA was synthesized 
using Superscript II (Invitrogen) and oligo dT, and real-time 
RT-PCR was carried out using the Applied BioSystem. The 
long isoform of CEACAM1 was amplified using the following 
primers: F: 5′-CAGCGCTGGCATACTTCCTT-3′, R: 5′-CACT 
TCCCCCGCCAGTCT-3′. As control, β-Actin was amplified 
using the primers: F: 5′-ATCAAGATCATTGCTCCTCCTGA-3′, 
R: 5′GAGCCACCAATCCACACAGAG-3′. At least one primer 
of each pair is located in the junction of two exons to avoid 
amplification of genomic DNA. Ct values (cycle threshold) were 
used to calculate the amount of amplified PCR product relative 
to β-Actin. The relative amount of mRNA was calculated as 2−ΔCT.
statistical analysis
Data were analyzed with SPSS software using one-factor ANOVA 
analysis or Student’s t-test. Values are expressed as mean ± SEM. 
AP < 0.05 obese versus lean/genotype.
FigUre 1 | carcinoembryonic antigen-related cell adhesion molecule 
1 (ceacaM1) level in human livers. Livers derived from anonymous 
obese (body mass index >30 kg/m2) 45- to 50-year-old male subjects and 
age-, sex-, and race-matched lean subjects. (a) CEACAM1 mRNA (CC1) 
was analyzed by Northern blot analysis of total liver mRNA and sequentially 
probed with cDNAs for CEACAM1 (CC1) followed by GAPDH for 
normalization. (B) Liver lysates from obese and lean subjects were analyzed 
by 4–12% SDS-PAGE followed by immunoblotting (Ib) with polyclonal 
antibody against CEACAM1 (CC1) and normalization against GAPDH. For 
simplicity, only two samples of each group are shown as representatives of 
three independent experiments. The graph on the right represents 
densitometry analysis of CEACAM1 bands relative to those of GAPDH in all 
tissues. Values shown as mean ± SEM with *P < 0.05 being statistically 
significant.
FigUre 3 | hepatic carcinoembryonic antigen-related cell adhesion 
molecule 1 (ceacaM1) level in obese rodents. Ceacam1 mRNA was 
analyzed by qRT-PCR analysis of total liver RNA, normalized to β-Actin, from 
livers derived from obese fa/fa, ZDF, and Koletsky f/f rats and age-matched 
lean controls (n = 10/lean or obese/each strain). Values shown as 
mean ± SEM with *P < 0.05 being statistically significant.
FigUre 2 | carcinoembryonic antigen-related cell adhesion molecule 
1 (ceacaM1) level in human primary hepatocytes. Primary cells were 
derived from the livers of the same anonymous donors and analyzed by 
Western analysis as in Figure 1, immunoblotting (Ib) with polyclonal antibody 
against CEACAM1 (CC1) and normalizing against GAPDH. For simplicity, only 
two samples of each group are shown as representatives of three 
independent experiments. The graph on the right represents densitometry 
analysis of CEACAM1 bands relative to those of GAPDH in all cells. Values 
shown as mean ± SEM with *P < 0.05 being statistically significant.
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resUlTs
reduced hepatic ceacaM1 levels in 
Tissues from Obese humans
Northern analysis indicates that CEACAM1 mRNA levels, nor-
malized to GAPDH, are significantly lower (by ~>60%) in the 
liver of obese human subjects by comparison to those derived 
from their lean sex-, race-, and age-matched counterparts 
(Figure  1A). This translates into reduced hepatic CEACAM1 
protein levels in lysates derived from livers (Figure 1B) of obese 
human subjects, as assessed by Western blot analysis using Ib 
with antibodies against human CEACAM1 and GAPDH (to nor-
malize against total protein loading). Moreover, obese subjects 
exhibit hepatic fat accumulation, as assessed by the twofold to 
threefold higher hepatic TG level in obese subjects (50.2 ± 4.5 
versus 20.3 ± 2.2 mg/g liver tissue, P < 0.05).
reduced ceacaM1 Protein content in 
Primary hepatocytes from Obese humans
Because metabolic factors such as insulin and fatty acids regu-
late Ceacam1 expression in hepatocytes, with insulin inducing 
its transcription (15) and fatty acids repressing it (16), we then 
aimed to examine whether the decline in hepatic CEACAM1 
occurs at the hepatocyte level. To this end, we examined the 
protein level of CEACAM1 in primary hepatocytes derived from 
the same obese and lean subjects whose livers were used to assess 
hepatic CEACAM1 levels (see above). Western blot analysis using 
antibodies against human CEACAM1 for Ib indicates ~50% 
reduction (graph) in CEACAM1 protein level in primary 
hepatocytes derived from obese as compared to their sex- and 
age-matched lean counterparts (Figure 2).
reduced hepatic ceacaM1 levels  
in Obese rats
To investigate whether the reduction in hepatic CEACAM1 in 
obesity is common among species, we then examined mRNA 
levels of Ceacam1 in the livers of obese male rats. These include 
obese Zucker hyperphagic rats without diabetes (fa/fa) or with 
diabetes (Zucker Diabetic Fatty rats—ZDF) (17), and obese spon-
taneous hypertensive Koletsky rats (f/f) (18). qRT-PCR analysis 
revealed a ≥50% decrease in hepatic Ceacam1 mRNA levels in 
obese relative to lean rats (Figure 3). Consistent with a role for 
CEACAM1 in insulin clearance (6), obese rats display reduced 
insulin clearance (as measured by steady-state C-peptide/insulin 
molar ratio) and hyperinsulinemia (Table 1). As expected, they 
also exhibit elevated body weight, fasting plasma FFA, and plasma 
and hepatic TG levels (Table 1).
DiscUssiOn
Using several genetically modified mouse models of loss- and 
gain-of-function of Ceacam1, we have demonstrated that 
TaBle 1 | Biochemical parameters in obese rats.
Zucker fa/fa Zucker ZDF Koletsky (f/f)
lean Obese lean Obese lean Obese
Body weight (g) 254 ± 10 330 ± 9A 275 ± 11 352 ± 10A 315 ± 9 458 ± 12A
Insulin (ρM × 102) 3.0 ± 0.8 18.2 ± 1.6A 0.9 ± 0.1 7.2 ± 1.0A 1.0 ± 0.3 25.5 ± 0.6A
C-peptide (ρM × 103) 1.1 ± 0.2 3.3 ± 0.2A 1.3 ± 0.1 3.0 ± 0.4A 1.5 ± 0.4 5.2 ± 0.2A
C-peptide/insulin ratio 3.8 ± 0.6 1.8 ± 0.1A 15.7 ± 1.3 5.0 ± 0.5A 14.6 ± 0.6 2.0 ± 0.1A
FFA (mEq/l) 0.5 ± 0.0 1.4 ± 0.1A 0.6 ± 0.1 1.1 ± 0.2A 0.7 ± 0.1 1.1 ± 0.2A
TG (mg/dl) 14 ± 3 246 ± 42A 65 ± 3 531 ± 58A 112 ± 8 385 ± 29A
Hepatic TG (mg/g tissue) 23 ± 2 63 ± 7A 27 ± 3 73 ± 5A 34 ± 4 78 ± 9A
Frozen liver tissues and plasma were extracted from 10 obese and 10 age-matched lean overnight fasted rats. These include fa/fa (8 weeks of age); ZDF (12 weeks of age), and 
Koletsky f/f (16 weeks of age). Values are expressed as mean ± SEM. AP < 0.05 obese versus lean/genotype. C-peptide/insulin molar ratio was used as determinant of insulin 
clearance. FFA, free fatty acids; TG, triglycerides.
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CEACAM1 plays a critical role in promoting hepatic insulin 
clearance, and that its loss in the liver causes chronic hyperin-
sulinemia followed by systemic insulin resistance, altered lipid 
homeostasis, hepatosteatosis, and visceral obesity (5–7). That 
defective insulin clearance contributes significantly to these 
obesity-associated metabolic abnormalities has been demon-
strated in several species, including humans (19–22). Thus, it has 
become imperative to investigate whether hepatic CEACAM1 
level is commonly reduced among species. The current studies 
demonstrate that by comparison to lean controls, CEACAM1 
level is reduced in the liver of age- and sex-matched obese human 
subjects and in three rat models of obesity resulting from null 
mutation of leptin receptor (17, 23).
Although the data on human subjects need to be strength-
ened by a much larger cohort of patients, they are consistent 
with a report finding a marked decline in hepatic CEACAM1 
levels in 29% of 99 obese subjects with insulin resistance and 
non-alcoholic fatty liver disease, with a higher incidence of 
CEACAM1 loss in individuals with high-grade fatty liver and 
severe obesity, independently of type 2 diabetes (24). That this 
occurs independently of diabetes and fasting hyperglycemia is 
consistent with normal insulin secretion and fasting normo-
glycemia in Ceacam1 mutant mice (7). Moreover, sustained 
reduction of CEACAM1 protein content in primary hepatocytes 
derived from the same steatotic livers of obese donors demon-
strates that the defect in CEACAM1 expression occurs at the 
hepatocyte level. We have recently shown that the rise in fatty 
acids release from adipocytes during high-fat feeding of mice 
progressively represses Ceacam1 expression in the hepatocyte 
by activating a mechanism depending on the activation of per-
oxisome proliferator-activated receptor α by fatty acids (25) and 
that this bestows a positive feedback mechanism on fatty acid 
β-oxidation (12). When the loss of hepatic CEACAM1 reaches 
more than 50% and impairment of insulin clearance develops, 
chronic hyperinsulinemia followed by hepatic steatosis ensues 
(12). Increased lipolysis-driven hepatic fatty acid β-oxidation in 
humans with uncomplicated obesity (26) and its role in regulat-
ing hepatic de novo lipogenesis (27, 28) propose an important 
role for the loss of hepatic CEACAM1 in the regulation of lipid 
homeostasis in hepatocytes derived from obese humans.
Obese Zucker and Koletsky hyperphagic obese rats display 
a decline in their hepatic CEACAM1 content likely causing 
impaired insulin clearance and hyperinsulinemia. They also 
manifest elevated visceral obesity with high fasting plasma FFA, 
and an increase in plasma and hepatic TG levels, consistent with 
the phenotype of Ceacam1 mutant mice (5–7).
Similarly, rats selectively bred for low aerobic running capacity 
(LCR) exhibit metabolic syndrome, including hyperinsulinemia, 
insulin resistance, obesity, and hypertension. By comparison to 
age-matched high capacity runners (HCR) (29), they also exhibit 
hepatic steatosis (30). Hyperinsulinemia in LCR rats is associ-
ated with impaired hepatic insulin clearance in correlation with 
reduced Ceacam1 mRNA (29) and protein levels (14). Caloric 
restriction reduces their hyperinsulinemia, and subsequently, 
hepatic fatty acid synthase level and steatosis, in parallel to 
inducing hepatic CEACAM1 levels and normalizing hepatic 
insulin extraction to the level of HCR (14). Whether low hepatic 
Ceacam1 level in LCR by comparison to HCR is a cause or a 
consequence of increased release of plasma FFA from the white 
adipose tissue in these rats (12, 25) remains to be determined, 
but it is intriguing that CEACAM1 expression is modulated by 
the selection for low aerobic running capacity that leads to the 
metabolic anomalies of LCR rats.
In summary, the current studies demonstrate a strong associa-
tion between reduced CEACAM1 expression in hepatocytes with 
obesity, hepatic steatosis, and dyslipidemia across species and 
multiple rat strains.
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